Soins infirmiers en oncologie

Description
Veille informationnelle portant sur les soins infirmiers en oncologie

Sujets couverts
Rôles et compétences
Spécialités cliniques
Traitements et interventions
Organisation des soins
Expériences des patients
Publications d’associations professionnelles

Sources
PubMed
CINAHL Complete
Sites Web d’associations professionnelles
Réseaux sociaux d’associations professionnelles

Fréquence
Mensuelle

Bibliothécaire responsable
Ghislaine Orth
ghislaine.orth.chum@ssss.gouv.qc.ca



Catégorie:

Description

Rôles et compétences

Rôles et compétences

Formation et apprentissage

Spécialités cliniques

Oncologie médicale

Chirurgie oncologique

Radio-oncologie

Traitements et interventions

Traitements non-pharmacologiques

Approches complémentaires

Réadaptation, physiothérapie et ergothérapie

Éducation aux patients et littératie en santé

Organisation des soins

Organisation et unités de soins

Trajectoires de soins

Performance et indicateurs

Amélioration de la qualité et meilleures pratiques

Innovation

Expériences des patients

Expériences des patients

Participation des patients

Résultats rapportés par les patients

Survivance

Publications d'associations professionnelles

Canadian Association of Nurses in Oncology (CANO/ACIO)

  • Therapeutic breakthroughs in oncology: Enhancing treatment and management
    on 11 septembre 2025

    Can Oncol Nurs J. 2025 Jul 1;35(4):590-605. doi: 10.5737/23688076354590. eCollection 2025.ABSTRACTRecent advancements in oncology have significantly transformed cancer treatment and care management, offering new hope to patients worldwide. This literature review examines key therapeutic breakthroughs, including targeted therapies, immunotherapies, personalized medicine, and innovative drug delivery systems. These cutting-edge interventions have enhanced patient outcomes, improving survival rates and quality of life, but they have also introduced complexities in managing emerging side effects, care coordination, and resource allocation. This review discusses the implications of these therapies on patient care, the ethical considerations they entail, the management of side effects, and the pivotal role of oncology nurses in administering and managing these treatments. By exploring the current landscape and future directions of oncology therapies, including areas such as cancer vaccines and precision medicine, this article provides a comprehensive understanding of how these innovations are shaping the future of cancer care.PMID:40873601 | PMC:PMC12379890 | DOI:10.5737/23688076354590

Oncology Nursing Society (ONS)

  • Bridging the Gap: The Role of Shared Decision-Making in Addressing Racial and Ethnic Disparities in Prostate-Specific Antigen Screening
    on 16 mars 2026

    Oncol Nurs Forum. 2026 Feb 25;53(2):e26535281. doi: 10.1188/26.ONF.e26535281.ABSTRACTOBJECTIVES: To assess racial and ethnic differences in prostate-specific antigen (PSA) screening and shared decision-making (SDM) and examine whether SDM modifies screening rates by race and ethnicity.SAMPLE & SETTING: Data from the 2021-2023 Behavioral Risk Factor Surveillance System were analyzed, including 10,778 men aged 55-69 years eligible for PSA screening.METHODS & VARIABLES: Descriptive statistics and chi-square tests assessed racial and ethnic differences in PSA screening and estimated SDM (eSDM) use. Multiple logistic regression models evaluated the impact of eSDM on PSA screening rates, including an interaction term for race and ethnicity and eSDM.RESULTS: Among the sample, 46% reported undergoing PSA screening in the past year. eSDM was a significant predictor of PSA screening. After adjusting for eSDM and covariates, racial disparities in screening rates were no longer significant. Only Asian American men showed a significantly lower likelihood of screening following SDM exposure compared to White men.IMPLICATION FOR NURSING: SDM can reduce racial and ethnic disparities in PSA screening. In addition, factors like healthcare access significantly influence screening rates, requiring targeted investigation. The results call for further investigation to culturally optimize SDM.PMID:41812019 | DOI:10.1188/26.ONF.e26535281

American Society of Clinical Oncology (ASCO)

  • Cancer Control in Refugee and Asylum Seeker Populations: A Scoping Review
    on 16 mars 2026

    JCO Glob Oncol. 2026 Feb;12:e2500307. doi: 10.1200/GO-25-00307. Epub 2026 Feb 20.ABSTRACTPURPOSE: Displaced individuals face significant health care access challenges, particularly for noncommunicable diseases. For these individuals, cancer control remains a severely neglected aspect of health care. This scoping review aims to synthesize and evaluate the current state of knowledge on equity within the cancer care continuum for refugee and asylum seeker populations worldwide.METHODS: A systematic search of PubMed and Embase was conducted for peer-reviewed articles published between 2000 and 2024, focusing on refugee and asylum seeker populations and cancer. Eligible studies addressed at least one stage of the cancer care continuum (prevention, detection, diagnosis, treatment, end-of-life care or survivorship) and included perspectives or outcomes of patients, caregivers, or providers. Data were extracted and mapped by study setting, population, cancer continuum stage, and type of barriers or interventions identified.RESULTS: Of 372 screened articles, 111 met inclusion criteria. The majority of research focused on cancer prevention, detection, and diagnosis. Common themes included low cancer awareness, reduced screening uptake, delayed diagnoses, treatment interruptions, and poor survival outcomes. Financial, social, and systemic barriers such as cost, stigma, language barriers, and inconsistent policies were frequently reported. Effective interventions included culturally tailored education, refugee-specific health clinics, use of interpreters, sex-concordant providers, and community engagement.CONCLUSION: Refugees and asylum seekers face persistent and multifaceted inequities in cancer care, shaped by both individual and systemic factors. Although some high-performing models and interventions exist, large gaps remain in research and service delivery. The findings emphasize the urgent need for an integrated strategy that incorporates the comprehensive cancer care needs of refugees and asylum seekers into national and international health policies.PMID:41719506 | DOI:10.1200/GO-25-00307

National Comprehensive Cancer Network (NCCN)

  • Five-Year Outcomes After Prostate-Specific Membrane Antigen PET/CT-Guided Salvage Radiotherapy Following Radical Prostatectomy
    on 16 mars 2026

    J Natl Compr Canc Netw. 2026 Feb;24(2):11-18. doi: 10.6004/jnccn.2025.7102.ABSTRACTBACKGROUND: Salvage radiotherapy (sRT) is the standard of care for biochemical recurrence of prostate cancer following radical prostatectomy (RP). In this context, prostate-specific membrane antigen (PSMA) PET/CT offers superior sensitivity and specificity for the detection of recurrent disease. We aimed to evaluate the impact of PSMA PET/CT-guided management on clinical outcomes following sRT.PATIENTS AND METHODS: We retrospectively screened 5 prospective PSMA PET/CT studies conducted between 2016 and 2021. Eligible patients underwent PSMA PET/CT for restaging at first biochemical recurrence after RP, received sRT, and had ≥24 months of follow-up. Progression-free survival (PFS), freedom from distant progression, and overall survival (OS) were calculated using the Kaplan-Meier method. Adjusted hazard ratios (aHRs) for PFS were derived using Cox proportional hazards regression, adjusting for age, pre-sRT prostate-specific antigen (PSA) level, use of androgen deprivation therapy (ADT), and receipt of whole-pelvis radiotherapy (WPRT).RESULTS: Of the total cohort, 113 patients met the inclusion criteria. Median follow-up was 59.4 months (IQR, 47.4-69.5). Median PSA was 0.4 ng/mL (IQR, 0.3-1.1), and the median time from RP was 19.9 months (IQR, 5.6-51.8). On PSMA PET/CT, 19 (16.8%) patients were staged as TrN0M0, 32 (28.3%) as N1M0, 16 (14.2%) as M1, and 46 (40.7%) as T0N0M0 (no visible disease). ADT was administered to 76 (67.3%) patients, and 63 (55.8%) patients received WPRT. Disease progression occurred in 57 (50.4%) patients. Median PFS was 49.2 months (95% CI, 24.1-74.3), and median freedom from distant progression was 76.4 months (95% CI, 62.9-89.9). The 5-year OS rate was 97.1% (95% CI, 94.1%-100%). Receipt of WPRT was significantly associated with improved PFS among patients staged as TrN0M0 (aHR, 0.12; P=.035), whereas ADT was significantly associated with improved PFS in patients staged as N1/M1 (aHR, 0.37; P=.024).CONCLUSIONS: In this 5-year follow-up study from an institution that was an early adopter of PSMA PET/CT, PSMA PET/CT-guided sRT was associated with favorable oncologic outcomes. Exploratory analyses suggest a potential benefit of WPRT following a positive PSMA PET/CT and of ADT in patients with N1/M1 disease.PMID:41698328 | DOI:10.6004/jnccn.2025.7102

European Society for Medical Oncology (ESMO)

 

Pour obtenir les documents
L’accès au texte intégral des documents est restreint au personnel et aux médecins du CHUM en fonction des abonnements de la bibliothèque.  Certains documents sont en accès libre sur le web.

Si vous êtes branchés sur le réseau CHUM :
Cliquer sur les liens fournis pour chaque référence pour vérifier la disponibilité du texte intégral.
Pour les articles provenant de PubMed, cliquer préalablement sur le lien suivant pour afficher la disponibilité du document.

Si vous êtes dans un autre établissement et que vous n’arrivez pas à accéder au texte intégral d’un article à partir du lien donné, vérifier auprès de la bibliothèque de votre institution en donnant la référence complète du document.


Avis de non-responsabilité

  • 1. EXCLUSION DE GARANTIES ET LIMITATION DE RESPONSABILITÉ

Le contenu des veilles informationnelles ou stratégiques (ci-après appelée « Veilles ») est mis à votre disposition à titre informatif pour un usage personnel exclusif. Tout usage commercial du contenu des Veilles est strictement interdit.

Tous les éléments, articles, rapports ou toute autre source d’information figurant dans les Veilles, vous sont fournis « tels quels », sans garantie d’aucune sorte. Eu égard aux propos tenus dans les articles et les rapports sélectionnés pour les Veilles, le CHUM n’offre aucune garantie notamment d’exhaustivité, de fiabilité, d’actualité et d’exactitude.Le CHUM ne pourra en aucun cas être tenu responsable envers quiconque de tout dommage quel qu’il soit, même ceux directs, encouru notamment des suites de toute réclamation, action ou poursuite découlant, même directement, de l’utilisation de ces Veilles.

  • 2. RESPONSABILITÉ RELATIVES AUX LIENS

Les Veilles contiennent des liens vers des sites Web créés et mis à jour par des tierces parties. Ces liens sont fournis pour la commodité des utilisateurs seulement. Le CHUM n’endosse et ne garantit, ni explicitement ni implicitement, l’exactitude ou l’intégralité ni du contenu de ces hyperliens ni des opinions qui y sont exprimées.

Le CHUM n’assume aucune responsabilité à l’égard de ces sites Web externes.

  • 3. PROPRIÉTÉ INTELLECTUELLE

Le CHUM prend tous les moyens raisonnables afin de respecter les droits de propriété intellectuelle afférents au contenu des Veilles et aux modalités du prêt entre bibliothèques, émises par l’Université de Montréal. Le contenu des Veilles, incluant la manière dont il est présenté, sont notamment protégés par la Loi sur le droit d’auteur (L.R.C. (1985), ch. C-42).

Le CHUM ne donne aucune garantie et ne fait aucune déclaration à l’effet que le contenu de ces veilles n’enfreint aucun droit d’une autre personne ou entité.

Le téléchargement, la reproduction en un seul exemplaire ou le tirage sur papier des Veilles ne sont autorisés qu’à des fins de sauvegarde et pour un usage privé et non commercial. Tout téléchargement, reproduction, édition, diffusion sur Internet, utilisation à des fins commerciales ou publiques, distribution, publication sur un autre site ou sur quelque autre forme ainsi que toute autre utilisation est strictement interdite, à moins d’être faite dans le respect des règles de propriété intellectuelle applicables.